Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040404 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
A Phase 2 study, sponsored by Cephalon.
- Terminated
- Registry status
- Phase 2
- Development phase
- 806
- Enrollment target
NCT00040404: Clinical Trial Phase 2 study, sponsored by Cephalon.
NCT00040404 is a Phase 2 study that was terminated before completion, run by Cephalon. The registered enrollment target is 806 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (506% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040404, a Phase 2 study, was terminated before completion, sponsored by Cephalon.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 806 participants
- Enrollment target
Study Summary
The purpose of this study is to establish safety for CEP-1347 and to determine an efficacious dose in the treatment of Parkinson's disease.
Primary Outcome
Number of participants with disability sufficient to require dopaminergic therapy was assessed according to the United Parkinson's Disease Rating Scale (UPDRS) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario.
Interventions
- OTHER Placebo Comparator
- DRUG CEP-1347 10mg
- DRUG CEP1347 25mg
- DRUG CEP-1347 50mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 806 participants |
| Start Date | 2002-03 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Why NCT00040404 stopped before completion
NCT00040404 is an interventional study that assigns participants to a tested intervention. The registered 806 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (506% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo Comparator is the first listed.
NCT00040404 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00040404 about?
NCT00040404 is a clinical study titled "Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease". The purpose of this study is to establish safety for CEP-1347 and to determine an efficacious dose in the treatment of Parkinson's disease.
What is the current status of trial NCT00040404?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 806 participants. The study started on 2002-03. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00040404?
The interventions under investigation include: Placebo Comparator (OTHER), CEP-1347 10mg (DRUG), CEP1347 25mg (DRUG), CEP-1347 50mg (DRUG).
Who is sponsoring clinical trial NCT00040404?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00040404's enrollment target sits among peer trials
806 36th of 2000 higher than 1,964 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia